News Releases

Servier Showcases Robust Presence at ASCO 2019

Agios to Present Clinical Data from its IDH Program at ASCO

Servier Cuts Ribbon on New Boston Headquarters

Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy

Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for Treatment of Newly Diagnosed AML with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy